Adding a MET gene inhibitor enhances the effect of combined chemotherapy and immunotherapy in small cell lung cancer (SCLC), ...

In India, we unfortunately still see presumptive TB diagnoses far too often — especially in younger patients with lung ...

Using genetic screening, scientists have found a new drug combination that works against some treatment-resistant lung, brain ...

A landmark study has revealed that autoantibodies-immune proteins traditionally associated with autoimmune disease-may ...

Lung cancer doesn’t just come from smoking. The amount of ultraprocessed food a person eats and drinks could be connected ...

Phase III data show Hernexeos can elicit a confirmed objective response rate of 48% in patients with HER2-mutated NSCLC who had previously been treated with a directed antibody-drug conjugate.

Bayer will partner with Kumquat Biosciences to develop Kumquat’s KRAS G12D inhibitor, which could generate $1.3 billion-plus for the San Diego biotech.

New research identifies NF-kappa-B-activating protein-like (NKAPL) as a potent tumor suppressor in non-small cell lung cancer (NSCLC).

TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.

A group of Australian scientists has uncovered a new way to fight some of the toughest cancers by targeting an overlooked ...